Angiotensin-Converting Enzyme Inhibitors
"Angiotensin-Converting Enzyme Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.
| Descriptor ID |
D000806
|
| MeSH Number(s) |
D27.505.519.389.745.085
|
| Concept/Terms |
Angiotensin-Converting Enzyme Inhibitors- Angiotensin-Converting Enzyme Inhibitors
- Angiotensin Converting Enzyme Inhibitors
- Inhibitors, Kininase II
- Kininase II Antagonists
- Kininase II Inhibitors
- Angiotensin I-Converting Enzyme Inhibitors
- Angiotensin I Converting Enzyme Inhibitors
- Antagonists, Angiotensin-Converting Enzyme
- Antagonists, Angiotensin Converting Enzyme
- Antagonists, Kininase II
- Inhibitors, ACE
- ACE Inhibitors
- Inhibitors, Angiotensin-Converting Enzyme
- Enzyme Inhibitors, Angiotensin-Converting
- Inhibitors, Angiotensin Converting Enzyme
- Angiotensin-Converting Enzyme Antagonists
- Angiotensin Converting Enzyme Antagonists
- Enzyme Antagonists, Angiotensin-Converting
|
Below are MeSH descriptors whose meaning is more general than "Angiotensin-Converting Enzyme Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Angiotensin-Converting Enzyme Inhibitors".
This graph shows the total number of publications written about "Angiotensin-Converting Enzyme Inhibitors" by people in this website by year, and whether "Angiotensin-Converting Enzyme Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 3 | 0 | 3 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 1 | 2 |
| 2008 | 2 | 1 | 3 |
| 2009 | 0 | 2 | 2 |
| 2011 | 1 | 1 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2020 | 1 | 2 | 3 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Angiotensin-Converting Enzyme Inhibitors" by people in Profiles.
-
Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction. Am J Cardiol. 2023 01 15; 187:84-92.
-
Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID-19. J Am Heart Assoc. 2021 12 21; 10(24):e023535.
-
Just the facts: What drugs are safe and effective for COVID-19? CJEM. 2020 Sep; 22(5):591-594.
-
The association of antihypertensive use and depressive symptoms in a large older population with hypertension living in Australia and the United States: a cross-sectional study. J Hum Hypertens. 2020 11; 34(11):787-794.
-
The Role of Angiotensin-Converting Enzyme Inhibitors and ?-Blockers in Primary Prevention of Cardiac Dysfunction in Breast Cancer Patients. J Am Heart Assoc. 2020 01 21; 9(2):e015327.
-
Does self-management counseling in patients with heart failure improve quality of life? Findings from the Heart Failure Adherence and Retention Trial (HART). Qual Life Res. 2014 Feb; 23(1):31-8.
-
Incidence and predictors of definite stent thrombosis after coronary stent implantation. Chin Med J (Engl). 2012 May; 125(9):1547-51.
-
Adherence to evidence-based guidelines for heart failure in physicians and their patients: lessons from the Heart Failure Adherence Retention Trial (HART). Congest Heart Fail. 2012 Mar-Apr; 18(2):73-8.
-
Management of angiotensin-converting enzyme inhibitor-induced angioedema. Laryngoscope. 2011 Nov; 121(11):2327-34.
-
Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway. Am J Pathol. 2011 Oct; 179(4):1719-32.